TMT-based proteomics analysis of the anti-hepatocellular carcinoma effect of combined dihydroartemisinin and sorafenib
Hepatocellular carcinoma (HCC), as the major primary liver cancer, is one of the most prevalent malignant diseases with a high mortality rate worldwide. Prior studies have demonstrated that dihydroartemisinin (DHA), the semisynthetic derivative of artemisinin, possesses anti−HCC activity. The multik...
Main Authors: | Chunying Hou, Dongqing Guo, Xue Yu, Shuyan Wang, Tianhua Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332220300524 |
Similar Items
-
Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
by: Omar Abdel-Rahman, et al.
Published: (2014-03-01) -
Sorafenib in the treatment of advanced hepatocellular carcinoma
by: Mousa Ali
Published: (2008-01-01) -
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
by: Hsu CH, et al.
Published: (2014-06-01) -
Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma
by: Ting Sun, et al.
Published: (2017-11-01) -
Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)